| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Inhibrx Biosciences Inc. (NASDAQ:INBX) shares rose 75.95% in after-hours trading on Thursday, closing at $49.90.
Check out the current price of INBX stock here.
According to Benzinga Pro data, the stock closed regular trading at $28.36, down 10.03%.
On Thursday, the California-based clinical-stage biopharmaceutical company announced positive topline results from the registrational ChonDRAgon study, a Phase 2 trial evaluating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma.
The 206-patient study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in median progression-free survival.
Ozekibart lowered the risk of disease progression or death by 52% compared with placebo, with a stratified hazard ratio of 0.479 and a 95% confidence interval of 0.33 to 0.68, and a P value of less than 0.0001.
Median PFS reached 5.52 months versus 2.66 months for placebo.
See Also: Wellgistics Health Stocks Spikes 88% After Hours On Blockchain Partnership
The company said Ozekibart is the first experimental therapy to demonstrate progression-free survival benefit in a randomized trial for chondrosarcoma, a cancer with no approved systemic treatments.
Inhibrx also reported results from expansion cohorts testing ozekibart with chemotherapy regimens.
Ozekibart combined with FOLFIRI showed a 23% overall response rate in late-line colorectal cancer patients, while the combination with irinotecan and temozolomide (IRI/TMZ) demonstrated a 64% overall response rate in patients with refractory Ewing sarcoma.
The stock of the biotechnology company has gained 84.16% so far this year.
Inhibrx Biosciences' shares closed Thursday at $28.36, falling 25.8% from their year-to-date high of $38.22 reached on Monday.
It has a 52-week range of $10.80 to $39.27 and a market capitalization of $410.81 million.
Benzinga's Edge Stock Rankings indicate that INBX has a positive price trend across all time frames. Know how its momentum lines up with other well-known names.
Read Next:
Photo Courtesy: Xharites on Shutterstock.com
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Posted In: INBX
